Compare AbbVie Inc (ABBV) vs Beyond Meat Inc (BYND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Beyond Meat Inc — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Beyond Meat Inc trades at $0.68 (market cap $366.00M). The key difference: AbbVie Inc is far larger — about 1229.3× Beyond Meat Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Beyond Meat Inc pays none. Which is the better fit depends on your goals.
| ABBV | BYND | |
|---|---|---|
Market Cap | $449.91B | $366.00M |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $4.28 |
52-Week Low | $184.85 | $0.52 |
Enterprise Value | $513.38B | $675.99M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
BYND trades at $0.7102, down slightly by 0.01% on the day, with a neutral technical signal and bearish moving averages. The company reported a net income of $178.01M in 2025, a significant turnaround from prior losses, though revenue declined to $275.50M. Recent news highlights expansion of Beyond Steak Filet into major retailers like Meijer and Wegmans, alongside new product launches such as Beyond Immerse protein drinks, aiming to revive growth amid challenging sales trends.
The outlook remains cautious due to persistent revenue declines and negative cash flow from operations, offset by strong profitability margins and positive net income. Risks include execution challenges in new product categories and high sell-side analyst skepticism, with 57.14% recommending sell. Investment opportunity hinges on successful turnaround efforts driving sustainable top-line growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
